Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2023 Vol. 1 > No. 2 > 100020
Next Article Previous Article
COMMENTARY   Open Access     Cite

Advancing the battle against Alzheimer's Disease: A focus on targeting tau pathology by antisense oligonucleotide

  • 1.

    Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China

  • 2.

    Department of Neurology, Lishui Hospital, Zhejiang University School of Medicine, Lishui 323000, China

More Information
  • Corresponding author: qingqingtao@zju.edu.cn
  • Received Date:  June 21, 2023
    Accepted Date:  August 10, 2023
    Published Online:  August 14, 2023
The Innovation Medicine  1(2),  https://doi.org/10.59717/j.xinn-med.2023.100020  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Jeong, S.Y., Suh, C.H., Shim, W.H., et al. (2022). Incidence of amyloid-related imaging abnormalities in patients with Alzheimer disease treated with anti-beta-amyloid immunotherapy: A meta-analysis. Neurology 99: e2092−e2101. DOI: 10.1212/WNL.0000000000201019.

    View in Article CrossRef Google Scholar

    [2] Zhang, Z., Li, X.G., Wang, Z.H., et al. (2021). delta-Secretase-cleaved Tau stimulates Abeta production via upregulating STAT1-BACE1 signaling in Alzheimer's disease. Molecular psychiatry 26: 586-603. DOI: 10.1038/s41380-018-0286-z.

    View in Article CrossRef Google Scholar

    [3] Lopera, F., Marino, C., Chandrahas, A.S., et al. (2023). Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man. Nature medicine 29: 1243-1252. DOI: 10.1038/s41591-023-02318-3.

    View in Article CrossRef Google Scholar

    [4] Arboleda-Velasquez, J.F., Lopera, F., O'Hare, M., et al. (2019). Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature medicine 25: 1680-1683. DOI: 10.1038/s41591-019-0611-3.

    View in Article CrossRef Google Scholar

    [5] Mummery, C.J., Borjesson-Hanson, A., Blackburn, D.J., et al. (2023). Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nature medicine 29:1437-1447. DOI: 10.1038/s41591-023-02326-3.

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Lin R.-R., Huang H.-F., and Tao Q.-Q. (2023). Advancing the battle against Alzheimer's Disease: A focus on targeting tau pathology by antisense oligonucleotide. The Innovation Medicine 1(2), 100020. https://doi.org/10.59717/j.xinn-med.2023.100020
    Lin R.-R., Huang H.-F., and Tao Q.-Q. (2023). Advancing the battle against Alzheimer's Disease: A focus on targeting tau pathology by antisense oligonucleotide. The Innovation Medicine 1(2), 100020. https://doi.org/10.59717/j.xinn-med.2023.100020

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(9038) PDF downloads(3567)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.